Toleranzia Ab
Toleranzia develops protein-based antigen-specific immune tolerogens to cure patients with autoimmune diseases. The drugs have the potential to become the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. The company has a lead project in myasthenia gravis as well as a second project in ANCA vasculitis. Toleranzia is listed on the Nasdaq First North Growth Market and backed by strongly committed renowned specialist investors.
7-day free trial · no credit card
Verified contacts
9
available on Kipplo
LinkedIn employees
9
1 to 10 range
Open roles
—
no listings
Distinct roles
8
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 9 verified contacts at Toleranzia Ab
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
9 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Toleranzia Ab
8 distinct titles indexed · top 8 shown.
- 1()
- 1board member
- 1cbo
- 1chief business officer
- 1media professional
- 1programme director
- 1research scientist
- 1senior research scientist
Sign up to unlock all 9 contacts at Toleranzia Ab
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 9 verified contacts at Toleranzia Ab
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.